drug
disposit
encompass
process
drug
absorpt
bloodstream
drug
metabol
differ
chemic
mainli
liver
intestin
distribut
variou
chemic
differ
tissu
remov
chemic
bodi
excret
organ
genet
makeup
might
play
part
activ
process
might
underli
chemic
toxic
advers
drug
reaction
meyer
address
problem
key
goal
predict
medicin
identifi
dna
loci
term
quantit
trait
loci
qtl
use
predict
respons
given
medic
toxic
particular
patient
eg
rost
et
al
harril
rusyn
challeng
easili
systemat
address
util
specif
mous
model
preclin
pharmacogenet
research
mous
pharmacogenet
studi
typic
appli
across
progeni
backcross
popul
rusyn
et
al
frick
et
al
across
recombin
inbr
ri
line
deriv
cross
two
founder
strain
inbreed
mani
gener
cook
et
al
hitzemann
et
al
across
predefin
collect
classic
inbr
line
montgomeri
et
al
yoo
et
al
although
approach
prove
use
mani
studi
deriv
mainli
mu
musculu
domesticu
thu
reflect
partial
repertoir
advers
effect
limit
pharmacogenet
investig
promis
new
model
organ
provid
recent
develop
collabor
cross
cc
strain
larg
genet
divers
mous
refer
popul
cc
panel
collect
ri
mous
line
combin
genom
eight
genet
phenotyp
divers
founder
nodshiltj
nzohlltj
casteij
pwkphj
wsbeij
aylor
et
al
consortium
wherea
first
five
founder
classic
mu
musculu
domesticu
subspeci
last
three
wildderiv
strain
repres
three
mu
musculu
subspeci
name
musculu
domesticu
mu
castaneu
thu
like
classic
ri
strain
cc
mice
genet
reproduc
balanc
allel
frequenc
addit
incorpor
larg
amount
genet
variat
dens
recombin
site
valdar
et
al
robert
et
al
yang
et
al
chesler
avail
genotyp
data
across
cc
line
open
way
analys
qtl
varieti
trait
includ
behavior
morpholog
phenotyp
aylor
et
al
chesler
mao
et
al
perciv
et
al
homeostat
immun
process
kelada
et
al
phillippi
et
al
suscept
infecti
diseas
durrant
et
al
ferri
et
al
vere
et
al
graham
et
al
gralinski
et
al
et
al
liverrel
function
kelada
et
al
svenson
et
al
thaisz
et
al
cc
popul
proven
phenotyp
divers
extent
drug
disposit
vari
across
strain
still
larg
unknown
rusyn
et
al
gelina
et
al
frick
et
al
one
mani
mechan
variat
drug
disposit
aris
biotransform
drug
liver
biotransform
drug
metabol
enzym
dme
drug
transport
protein
dtp
catalyz
biochem
modif
transport
exogen
chemic
xenobiot
katz
et
al
regard
hepat
drug
metabol
cc
line
two
key
question
aris
larg
divers
expect
hepat
biotransform
particular
drug
ii
cc
mice
use
evalu
crosstalk
drug
metabol
function
liver
especi
relat
lipid
fatti
acid
metabol
exploit
transcript
mechan
dissect
genet
variat
hepat
drug
metabol
cc
line
focu
cisregulatori
variant
underli
interindividu
variat
gene
express
genet
variant
refer
proxim
eqtl
central
understand
metabol
divers
owe
rel
larg
genet
effect
size
wittkopp
kalay
bryoi
et
al
plastic
proxim
factor
short
evolutionari
time
scale
wray
proxim
regulatori
variat
known
affect
metabol
trait
eg
hsieh
et
al
zhong
et
al
kang
et
al
organ
architectur
element
govern
hepat
drug
metabol
yet
subject
comprehens
character
leverag
rnasequenc
technolog
mortazavi
et
al
rosenkranz
et
al
parkhomchuk
et
al
gener
transcript
profil
liver
tissu
cc
line
individu
appli
eqtl
analysi
data
character
genet
control
express
drug
disposit
control
overal
express
gene
express
particular
transcript
isoform
use
predict
compil
network
connect
genom
loci
metabol
specif
drug
highlight
potenti
joint
genet
effect
drugdrug
interact
analysi
nuclear
receptor
particip
regul
cellularbiochem
pathway
provid
dna
variant
affect
crosstalk
lipid
metabol
drug
metabol
thu
studi
support
premis
cc
popul
valuabl
model
system
investig
genet
variat
respons
wide
rang
chemic
drug
may
offer
mechan
dna
variat
contribut
relationship
lipid
metabol
advers
clinic
effect
moreov
approach
provid
gener
strategi
systemlevel
map
eqtldrug
connect
across
genet
divers
popul
collabor
cross
cc
recombin
inbr
mous
line
use
describ
elsewher
iraqi
et
al
durrant
et
al
consortium
anim
hous
hardwood
chip
bed
open
top
cage
anim
facil
telaviv
univers
tau
lightdark
cycl
mice
given
tap
water
rodent
chow
ad
libitum
throughout
experi
liver
tissu
collect
old
male
cc
mice
tau
cohort
inbreed
gener
total
mice
cc
line
use
tabl
experiment
protocol
approv
institut
anim
care
use
committe
iacuc
tau
approv
protocol
accord
nation
guidelin
liver
tissu
dissect
subsequ
store
steril
tube
liquid
nitrogen
rna
extract
use
rneasi
plu
kit
procedur
qiagen
rna
qualiti
test
bioanalyz
agil
sampl
rna
integr
number
rin
exceed
rnaseq
librari
prepar
use
truseq
strand
mrna
librari
prepar
kit
illumina
librari
pool
sequenc
illumina
hiseq
sequenc
illumina
sequenc
chemistri
pairedend
sequenc
perform
read
base
end
fragment
overal
sampl
consist
rnasequenc
fragment
averag
fragment
data
access
geo
seri
access
number
detail
descript
data
analysi
appear
see
summari
comput
pipelin
tabl
rnaseq
data
map
quantifi
use
rsem
version
li
dewey
mous
genom
ucsc
annot
file
ensembl
version
refer
creat
rsem
rsempreparerefer
command
follow
calcul
express
level
gene
use
rsemcalculateexpress
command
analysi
appli
default
paramet
use
bowti
version
langmead
salzberg
overal
averag
percentag
unmap
fragment
min
max
averag
percentag
fragment
align
singl
gene
min
max
among
fragment
align
one
isoform
min
max
total
express
level
measur
rsem
fpkm
metric
defin
number
fragment
map
genom
region
gene
per
kilobas
gene
exon
per
million
map
fragment
isoformratio
level
contrast
defin
percentag
detect
fragment
map
given
altern
splice
isoform
gene
total
number
fragment
map
gene
rsem
isopct
metric
express
trait
gene
refer
either
overal
express
totalexpress
trait
percentag
specif
isoform
isoformratio
trait
follow
describ
transform
associ
test
step
appli
separ
trait
simplic
omit
index
gene
either
totalexpress
trait
isoformratio
trait
whenev
possibl
given
express
trait
denot
level
individu
vi
maxim
level
trait
denot
vm
max
vi
n
number
individu
bin
size
trait
defin
max
first
term
repres
accuraci
threshold
second
term
repres
maximum
level
let
vi
round
level
vi
accuraci
bin
size
base
round
level
van
der
waerden
normal
score
transform
lehmann
aylor
et
al
defin
ri
ui
adjust
level
trait
individu
p
quantil
function
normal
distribut
probabl
p
ri
rank
vi
among
n
valu
vn
tie
resolv
averag
rank
throughout
studi
refer
adjust
trait
ui
rather
origin
measur
associ
score
given
express
trait
given
genom
interv
calcul
regress
trait
contribut
eight
cc
founder
strain
previous
describ
mott
et
al
formal
given
genom
interv
trait
associ
score
likelihood
ratio
lr
null
model
ui
genet
model
mi
cc
line
ith
individu
gk
mi
haplotyp
probabl
kth
founder
k
cc
line
mi
intercept
valu
genet
fix
effect
kth
founder
random
effect
cc
line
error
term
assum
normal
distribut
n
covari
use
mix
model
regress
implement
r
use
packag
version
bate
et
al
fals
discoveri
rate
fdr
estim
compar
lr
valu
real
data
distribut
lr
valu
use
randomli
permut
dataset
throughout
studi
permut
fdr
calcul
cpermcreal
creal
cperm
denot
number
trait
lr
valu
exceed
certain
threshold
origin
real
dataset
permut
dataset
respect
cperm
averag
permut
dataset
order
permut
specif
random
fix
effect
genet
rather
random
effect
shuffl
appli
cc
line
label
appli
associ
test
gene
express
liver
vm
singl
isoformratio
trait
gene
isoform
highest
number
differ
round
level
set
vi
sinc
interest
variat
express
reduc
run
time
analysi
exclud
trait
low
number
differ
round
level
across
individu
altogeth
associ
test
appli
totalexpress
trait
isoformratio
trait
associ
test
appli
genotyp
dataset
obtain
unc
system
genet
repositori
http
csbiounceduccstatu
includ
measur
marker
genotyp
array
base
illumina
infinium
platform
genotyp
data
comput
valid
use
comparison
polymorph
loci
rnaseq
data
figur
given
genom
interv
haplotyp
probabl
gk
founder
k
cc
line
calcul
use
happi
packag
version
mott
et
al
altogeth
associ
test
appli
genom
interv
haplotyp
probabl
calcul
unless
state
otherwis
analysi
focus
proxim
genom
interv
end
associ
score
calcul
use
genom
interv
whose
distanc
gene
transcript
start
site
less
mbp
throughout
manuscript
use
follow
terminolog
proxim
eqtl
defin
nearbi
genom
interv
whose
fdr
lower
base
permut
two
type
proxim
eqtl
totalexpress
eqtl
associ
express
level
totalexpress
trait
isoformratio
eqtl
associ
percentag
altern
splice
isoform
see
tabl
full
list
note
possibl
use
optim
regress
paramet
equat
determin
contribut
founder
overal
regulatori
variat
previous
describ
aylor
et
al
durrant
et
al
defin
founder
effect
ab
higher
absolut
founder
effect
certain
eqtl
target
stronger
contribut
dna
chang
eqtl
region
founder
strain
eqtldrug
connect
map
gener
sever
step
step
assembl
refer
collect
manual
curat
drugspecif
set
enzym
set
collect
includ
group
gene
play
role
metabol
reaction
particular
drug
base
direct
experiment
evid
refer
collect
consist
gene
set
relat
differ
drug
assembl
kyoto
encyclopedia
gene
genom
kegg
ipa
databas
qiagen
redwood
citi
ca
step
addit
enzym
ad
set
base
indirect
evid
specif
manual
curat
set
expand
altern
gene
chemic
reaction
ec
number
altogeth
step
produc
refer
collect
drugspecif
gene
set
assign
gene
particular
set
base
either
direct
step
indirect
step
experiment
evid
next
step
remov
gene
associ
proxim
eqtl
particular
given
refer
collect
step
retain
gene
significantli
associ
least
one
proxim
eqtl
use
threshold
detail
see
final
collect
tabl
build
collect
eqtldrug
connect
map
consist
three
type
node
drug
least
one
nonempti
curat
gene
set
gene
nonempti
set
proxim
eqtl
gene
map
contain
edg
drug
node
correspond
node
gene
well
edg
gene
node
node
proxim
eqtl
demonstr
altern
splice
event
particular
gene
given
sampl
read
align
genom
use
tophat
version
kim
et
al
thu
avoid
case
align
fragment
two
nearbi
gene
uniqu
map
read
extract
filter
read
carri
poor
map
qualiti
use
tophat
align
igv
softwar
et
al
use
show
read
coverag
togeth
amount
splice
junction
see
detail
investig
transcript
divers
liver
cc
mice
sequenc
total
rna
liver
distinct
cc
line
individu
per
strain
individu
total
tabl
basi
data
quantifi
total
express
gene
totalexpress
trait
well
rel
express
annot
isoform
isoformratio
trait
see
materi
method
tabl
found
global
express
profil
similar
individu
strain
totalexpress
isoformratio
trait
figur
dataset
therefor
amen
studi
follow
focu
total
express
trait
isoformratio
trait
highli
variabl
across
cc
mice
test
associ
trait
separ
polymorph
genomewid
map
indic
expect
analysi
spuriou
transeqtl
band
figur
show
inflat
associ
test
statist
figur
analysi
focus
proxim
eqtl
use
cutoff
mbp
evid
ci
regulatori
variat
permiss
genom
rang
select
account
lack
precis
associ
genom
interv
figur
use
permut
establish
null
distribut
associ
test
statist
exploit
null
distribut
calcul
permutationbas
fals
discoveri
rate
permut
fdr
score
see
materi
method
permut
fdr
identifi
proxim
eqtl
associ
total
express
gene
totalexpress
eqtl
associ
express
specif
transcript
isoform
isoformratio
eqtl
total
significantli
associ
trait
see
materi
method
tabl
note
similar
number
totalexpress
eqtl
isoformratio
eqtl
accord
previou
studi
human
cohort
et
al
battl
et
al
gene
found
dual
annot
totalexpress
isoformratio
trait
obtain
totalexpress
eqtl
isoformratio
eqtl
necessarili
genom
interv
character
biochem
network
context
inherit
transcript
variat
examin
eqtlassoci
trait
found
enrich
curat
list
biotransform
reaction
ingenu
pathway
analysi
ipa
databas
p
hypergeometr
test
specif
drug
disposit
gene
found
associ
proxim
eqtl
could
classifi
accord
particular
type
enzymat
reaction
tabl
function
reaction
oxid
reduct
hydrolysi
either
activ
detoxifi
drug
among
eqtlassoci
function
dme
oxid
catalyz
cytochrom
alcohol
aldehyd
dehydrogenas
thioldisulfid
oxidoreductas
fmo
reduct
catalyz
aldoketo
reductas
hydrolysi
catalyz
variou
esteras
siae
epoxid
hydrolas
dihydropyrimidinas
dpi
glucuronidas
gusb
glyoxalas
conjug
reaction
transfer
function
group
cofactor
substrat
chemic
result
detoxif
follow
excret
eqtlassoci
conjug
dme
catalyz
transfer
variou
function
group
includ
udpglucuronosyl
amino
acid
nacetyl
methyl
glutathion
tpmt
respect
transport
reaction
mediat
dtp
role
facilit
carri
drug
across
cellular
membran
katz
et
al
penner
et
al
eqtl
target
class
includ
two
type
dtp
famili
atpbind
cassett
solutelink
carrier
transcript
regul
identifi
eqtl
target
includ
car
nuclear
receptor
regul
transcript
drug
disposit
enzym
obtain
global
perspect
particip
eqtl
drug
metabol
use
expertcur
drugspecif
set
enzym
set
collect
enzym
play
role
biotransform
one
particular
drug
see
materi
method
analyz
set
identifi
drug
whose
biotransform
perturb
least
one
proxim
eqtl
tabl
affect
two
eqtl
resid
distinct
genom
locat
least
mb
apart
tabl
organ
inform
network
refer
eqtldrug
connect
map
figur
map
compos
three
type
node
drug
eqtl
enzym
drug
connect
metabol
enzym
node
enzym
connect
underli
eqtl
node
character
drug
term
perturb
eqtl
provid
potenti
joint
effect
may
underli
respons
administr
drug
exampl
trichloroethylen
tce
small
molecul
carcinogen
potenti
connect
map
tce
connect
three
eqtl
target
cytochrom
cyp
glutathion
stransferas
gst
amino
acid
aa
transferas
connect
map
base
known
biochem
pathway
involv
combin
eqtl
target
figur
left
biochem
pathway
suggest
potenti
process
joint
genet
effect
may
influenc
respons
tce
irinotecan
pathway
provid
anoth
exampl
potenti
genet
interact
within
eqtldrug
connect
map
figur
right
irinotecan
drug
use
treatment
cancer
nagar
blanchard
known
individu
differ
suscept
effect
nagar
blanchard
guo
et
al
marsh
hoskin
pathway
consist
activ
irinotecan
member
carboxylesteras
ce
famili
deactiv
udpglucuronosyltransferas
ugt
glucuronidas
famili
overal
wherea
eqtldrug
connect
map
figur
summar
ident
relev
metabol
enzym
mechanist
visual
figur
suggest
exist
genet
interact
differ
eqtl
along
cascad
metabol
reaction
addit
connect
map
indic
associ
enzym
particip
biotransform
two
drug
highlight
potenti
regulatori
variat
may
lead
drugdrug
interact
one
exampl
solutelink
carrier
whose
proxim
regulatori
variat
probabl
effect
least
seven
drug
includ
lovastatin
bosentan
cimetidin
anoth
exampl
famili
udpglucuronosyl
transferas
ugt
connect
differ
drug
suggest
specif
proxim
regulatori
variat
influenc
larg
repertoir
drug
note
possibl
identifi
group
cc
line
basi
covari
express
drugspecif
metabol
enzym
exampl
case
irinotecan
pathway
figur
clear
group
cc
line
base
covari
express
across
relev
enzym
eg
distinct
express
line
compar
line
across
express
gusb
base
group
possibl
select
nonredund
subset
line
cover
larg
varieti
respons
eg
choos
singl
line
group
distinct
drug
initi
differ
biotransform
pathway
perturb
distinct
combin
eqtl
strategi
may
provid
tailor
drugspecif
select
cc
line
open
way
futur
expressionbas
select
repres
cc
line
use
test
advers
effect
pharmacogenet
studi
data
show
substanti
fraction
identifi
associ
result
splice
variabl
among
associ
trait
found
isoformratio
trait
tabl
furthermor
observ
similar
percentag
isoformratio
trait
within
associ
drug
deposit
gene
trait
tabl
tce
pathway
instanc
seven
associ
gene
identifi
four
whose
associ
due
variat
splice
event
span
four
differ
metabol
transform
end
tce
oxid
chloral
dcvg
dcvt
figur
left
similarli
among
six
associ
gene
irinotecan
pathway
four
control
level
altern
splice
gusb
figur
right
result
compar
report
isoformratio
percentag
human
caucasian
yoruba
cohort
individu
respect
et
al
agreement
studi
indic
isoformratio
eqtl
preval
less
abund
totalexpress
eqtl
eg
battl
et
al
turn
character
repres
exampl
isoformlevel
associ
eqtlassoci
gene
first
select
founder
strain
differ
substanti
effect
chose
cc
line
carri
haplotyp
select
founder
associ
locu
eqtl
gene
note
cc
line
gene
select
carri
genet
inform
founder
lead
major
variat
fraction
express
least
one
isoform
select
cc
line
therefor
show
distinct
distribut
splice
junction
focu
two
gene
gene
first
exemplifi
abovement
cc
select
procedur
show
splice
junction
select
strain
next
analyz
regulatori
program
ligandactiv
transcript
factor
call
nuclear
receptor
nr
nr
select
play
major
role
transcript
regul
also
sinc
mani
dme
dtp
induc
substrat
activ
nr
chemic
signal
ligand
nr
consist
exogen
drug
xenobiot
well
endogen
small
molecul
steroid
hormon
cholesterol
eg
evan
mangelsdorf
use
extens
map
regulatori
program
within
curat
ipa
identifi
seven
differ
nr
receptor
complex
whose
target
enrich
among
associ
trait
figur
specif
found
enrich
target
xenobiot
drugactiv
nr
includ
xenobiot
sensor
without
heterodimer
partner
p
respect
hypergeometr
test
xenobiot
sensor
car
heterodim
p
also
found
hepat
eqtl
target
enrich
known
target
three
nr
activ
cholesterol
fatti
acid
ligand
p
respect
map
nrdepend
eqtl
target
show
clear
overlap
target
xenobioticssensit
regul
target
lipidsensit
regul
figur
specif
six
gene
regul
xenobiot
sensor
pxr
car
also
regul
lipid
sensor
close
examin
map
show
overlap
lipid
metabol
drug
metabol
even
promin
known
dme
gene
target
lipidsens
nuclear
receptor
similarli
two
gene
control
xenobioticsactiv
receptor
wellestablish
lipid
metabol
enzym
result
consist
known
biochem
reaction
may
act
unrel
compound
exampl
role
degrad
steroid
addit
role
oxid
varieti
drug
includ
tamoxifen
paclitaxel
haloperidol
tretinoin
similarli
particip
hepat
degrad
also
conjug
levothyroxin
nicotin
irinotecan
figur
furthermor
analysi
consist
previou
report
human
mous
disord
lipid
metabol
effect
clinic
drug
disposit
way
around
exampl
nonalcohol
fatti
liver
diseas
nafld
patient
exhibit
alter
metabol
drug
buechler
weiss
dtp
downregul
nonalcohol
steatohepat
nash
subject
lake
et
al
furthermor
sever
genet
modifi
nafld
nash
document
effect
efficaci
drug
review
naik
et
al
result
cc
panel
demonstr
preval
genet
variat
act
lipiddrug
crosstalk
cc
mice
therefor
use
investig
relationship
factor
role
interact
lipid
metabol
metabol
drug
xenobiot
central
challeng
pharmaceut
research
investig
genet
variat
respons
drug
chemic
xenobiot
panel
cc
line
promis
model
pharmacogenom
studi
larg
amount
genet
variat
abil
investig
molecular
respons
drug
within
special
intern
tissu
howev
effect
genet
variat
drug
disposit
enzym
remain
elucid
defin
divers
complex
genet
variat
express
drug
disposit
gene
across
cc
line
result
indic
previous
unknown
overrepresent
hepat
drug
disposit
gene
affect
proxim
regulatori
variat
p
tabl
inspect
show
complex
interrelationship
regulatori
variant
highlight
variou
potenti
interact
drug
due
share
eqtl
figur
analysi
therefor
provid
inform
view
guid
futur
pharmacogenet
mechanist
studi
across
cc
strain
exampl
found
signific
effect
lipid
metabol
pharmacokinet
paramet
figur
suggest
cc
mice
suitabl
model
studi
lipiddrug
crosstalk
human
metabol
disord
measur
toxic
advers
effect
across
larg
popul
genet
distinct
individu
costli
analysi
offer
potenti
strategi
select
subset
cc
line
design
specif
drug
use
pharmacogenom
studi
particular
given
drug
correspond
group
eqtl
target
play
role
deposit
drug
eg
six
dme
irinotecan
pathway
figur
transcript
profil
cc
line
across
gene
group
may
point
small
subset
nonredund
cc
line
eg
irinotecan
pathway
singl
cc
line
eight
group
figur
subsequ
pharmacogenet
studi
drug
subset
cc
line
analyz
strategi
contrast
standard
approach
choos
line
accord
genotyp
two
select
method
complement
expressionbas
approach
may
reveal
addit
function
effect
candid
genom
loci
although
yet
known
whether
select
cc
mice
base
proxim
eqtl
reflect
drug
toxic
advers
effect
vivo
provid
plausibl
strategi
ration
select
strain
reli
variat
transcript
isoform
addit
overal
express
gene
ii
tailor
specif
drug
iii
allow
select
addit
cc
mice
includ
refer
databas
eg
use
infer
trait
level
base
optim
paramet
equat
futur
studi
determin
whether
expressionbas
cc
select
strategi
predict
drug
toxic
advers
outcom
complet
approach
requir
integr
addit
genom
data
includ
proteom
transact
polymorph
loci
epigenet
data
author
list
made
substanti
direct
intellectu
contribut
work
approv
public
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
